Empirical Financial Services LLC d.b.a. Empirical Wealth Management Raises Stock Position in Boston Scientific Corporation $BSX

Key Points

• Empirical Financial Services LLC increased its stake in Boston Scientific Corporation by 21.5%, owning 26,471 shares valued at approximately $2.84 million.
• Boston Scientific reported a 22.8% increase in revenue year-over-year, with quarterly earnings of $0.75 EPS, surpassing analyst expectations of $0.72.
• Analysts maintain a consensus "Buy" rating for Boston Scientific, with an average target price of $120.79 and significant stake increases from various hedge funds.

Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 21.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,471 shares of the medical equipment provider's stock after acquiring an additional 4,690 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management's holdings in Boston Scientific were worth $2,843,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after buying an additional 1,536,663 shares in the last quarter. Swedbank AB grew its stake in Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider's stock worth $302,816,000 after buying an additional 1,505,019 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock worth $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Up 1.1%

NYSE:BSX opened at $97.30 on Friday. The company has a fifty day moving average of $102.93 and a 200 day moving average of $102.05. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $144.17 billion, a P/E ratio of 57.91, a P/E/G ratio of 2.32 and a beta of 0.61.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business posted $0.62 EPS. The firm's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares of the company's stock, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Royal Bank Of Canada reissued an "outperform" rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Canaccord Genuity Group boosted their price target on shares of Boston Scientific from $131.00 to $132.00 and gave the stock a "buy" rating in a research note on Wednesday. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Finally, UBS Group boosted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $120.79.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.